The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC)

BACKGROUND: No data exist to suggest PARP inhibitor (PARPi) therapy as first-line maintenance is superior to PARPi therapy as second-line maintenance. OBJECTIVE: To determine the efficacy and cost of primary versus secondary olaparib or niraparib maintenance in Epithelial Ovarian Cancer (EOC). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Peter G, Yao, Meng, Chambers, Laura M, Mei, Lin, Le, Phuc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8681231/
https://www.ncbi.nlm.nih.gov/pubmed/34925959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8681231/
https://www.ncbi.nlm.nih.gov/pubmed/34925959

Ejemplares similares